$0.34
-0.61%
N/A-$0.00
Healthcare
Biotechnology
NASDAQ
활발히 거래 중
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages ...
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine enterprise operating across the United States, Canada, and Europe. The company primarily engages ...
CollPlant Biotechnologies Ltd. (CLGN) is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues/organs and medical aesthetics. Its core platform is plant-based recombinant human Type I collagen (rhCollagen) produced through proprietary genetic engineering technology, which underpins bioprinting bioinks/matrices and injectable/dermal aesthetic products. The business model is ...
CollPlant Biotechnologies Ltd. (CLGN) is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues/organs and medical aesthetics. Its core platform is plant-based recombinant human Type I collagen (rhCollagen) produced through proprietary genetic engineering technology, which underpins bioprinting bioinks/matrices and injectable/dermal aesthetic products. The business model is commercialization of enabling materials plus downstream medical products, supported by collaborations with partners across bioprinting ecosystems and healthcare development. From a fundamentals standpoint, the most visible issue is profitability and cash generation. TTM margins are deeply negative: gross margin is about -3.19%, operating margin about -33.29%, EBITDA margin about -30.93%, and net margin about -33.76%. Returns are also sharply negative (ROA ~ -1.43, ROE ~ -1.60), consistent with a company still in development/commercial scaling mode rather than steady-state profitability. Valuation ratios derived from earnings are not meaningful (P/E is negative), and free-cash-flow metrics are unfavorable (free cash flow yield about -2.86% on an enterprise basis; EV/Free Cash Flow ~ -0.21), indicating the market is effectively pricing for future success rather than current earnings power. Balance-sheet liquidity appears comparatively supported: current ratio (TTM) is ~2.27 and quick ratio is ~1.99, suggesting near-term coverage of obligations. However, the company’s cash generation remains weak (operating cash flow coverage ratios are negative and interest coverage is negative), and leverage is moderate (debt-to-equity ~0.54). This combination typically increases reliance on continued funding—whether through operations, capital markets, partnerships, or other financing. Net, CLGN has a potentially defensible platform (collagen sourcing/material manufacturing capability) but currently demonstrates pre-profit execution risk. For long-term investors, the key question is whether clinical/regulatory progress and commercialization can translate into sustained revenue growth and improving margins before additional dilution or funding constraints become dominant.
총이익률, 영업이익률, 순이익률이 전년 대비 어떻게 바뀌었는지 보여줍니다.
| 지표 | 현재 | 이전 | 전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다. | 전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다. | 신호 |
|---|---|---|---|---|---|
| 매출 | — | — | — | — | 보합 |
| 희석 EPS | — | — | — | — | 보합 |
| 잉여현금흐름 | — | — | — | — | 보합 |
| 지표 | 현재 | 이전 | 전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다. | 전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다. | 신호 |
|---|---|---|---|---|---|
| 순이익률 | — | -4242.47% | — | — | 보합 |
| 영업이익률 | — | -4267.12% | — | — | 보합 |
| ROE | — | — | — | — | 보합 |
| 지표 | 현재 | 이전 | 전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다. | 전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다. | 신호 |
|---|---|---|---|---|---|
| 유동비율 | — | 2.268 | — | — | 보합 |
| 당좌비율 | — | 1.990 | — | — | 보합 |
| 부채 / 자본 | — | 0.542 | — | — | 보합 |
| 지표 | 현재 | 이전 | 전년 대비전년 동기 대비 변화: 현재 분기와 전년 동기 분기를 비교합니다. | 전분기 대비전분기 대비 변화: 현재 분기와 직전 분기를 비교합니다. | 신호 |
|---|---|---|---|---|---|
| P/E | — | -0.58x | — | — | 보합 |
| P/B | — | 1.51x | — | — | 보합 |